Gilead Sciences has acquired the TREX1 cancer programme from Sprint Bioscience for an upfront payment of $14 million plus milestone payments up to $400 million. The objective of the TREX1 programme, which is in the preclinical phase, is to develop drugs that inhibit the TREX1 protein in order to enhance the efficacy of immuno-oncology therapy, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!